Drilldown: Medicines
Medicines > routes:
Oral 
& duration :
2-4 hours; headache recurrence rate ~20-30% within 24 hours or
6-12 hours
& duration :
2-4 hours; headache recurrence rate ~20-30% within 24 hours or
6-12 hours Use the filters below to narrow your results.
brand:
classes:
[[:Category:Analgesics|Analgesic]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Antimigraine medicines|Antimigraine medicine]] (1) ·
[[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) ·
[[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) ·
[[:Category:Thiazide_diuretics|Thiazide diuretic]] (1) ·
[[:Category:Triptans|Triptan (5-HT1B/1D agonist)]] (1)
mechanism:
None (1) ·
'"`UNIQ--vote-00000138-QINU`"' Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern'"`UNIQ--ref-00000139-QINU`"'. (1) ·
'"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"' (1) ·
'"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1)
starting dose:
preparations:
10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) ·
12.5 mg capsules; 12.5, 25, 50 mg tablets (1) ·
Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) (1)
fda max:
routes: (Click arrow to add another value)
onset:
duration: (Click arrow to add another value)
halflife:
bioavailability:
pregnancy:
None (1) ·
Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 3 results in range #1 to #3.